Bolivia Medical Device Registration: Apostille versus Consular Legalisation after May 2018

1. Key takeaways

Bolivia has been a party to the Hague Convention Abolishing the Requirement of Legalisation for Foreign Public Documents since 7 May 2018, so in principle a public document issued in China can be authenticated by an apostille instead of the full consular legalisation chain. Section 2.3.2 of the manual, however, still describes the certificate of free sale as issued or endorsed by the national health authority of the country of origin and legalised by a Bolivian consulate, wording that predates the accession. GRZAN’s working position is to prepare on the basis of an apostille while confirming the currently accepted position with AGEMED in writing: neither assuming unilaterally nor reverting to the slow full chain.

The situation is a familiar one in markets whose guidance documents lag behind their treaty obligations. The treaty creates a legal entitlement, and the manual describes an earlier practice. Between the two sits an examiner applying the document list, and the only reliable way to know which route will be accepted on a given day is to ask, in writing, before the documents are produced.

The cost of getting this wrong is asymmetric. Preparing an apostille and discovering that legalisation is required means repeating the authentication step; preparing full legalisation and discovering that an apostille would have sufficed means paying for time that was never needed. A written confirmation resolves the question at negligible cost, which is why it belongs at the start of the document chain rather than in the middle of it.

2. Legal basis

Two of the four instruments are treaties or statutes and two are procedural guidance. The Apostille Convention governs the authentication of public documents between states party to it; Decreto Supremo N° 25235 governs the representation relationship between the manufacturer and the importing enterprise; sections 2.3.2 and 2.3.4 of the manual translate both into document requirements for a device file. Because the manual is administrative guidance rather than a statute, its text can lag behind the treaty without creating a legal conflict: the treaty governs the obligation, the manual describes the practice, and the authority’s current position determines what will be accepted at the counter.

3. Expert insights

Insight 1: the gap between the manual text and the treaty status is a fact, not an oversight to be argued. When the manual was written, Bolivia had not yet acceded to the convention, which is why the clause still reads consular legalisation. After entry into force the clause was not revised in step. Text that lags behind an international obligation is not unusual in Bolivia, and the only sound response is confirmation rather than inference: a manufacturer cannot rely on the treaty in the abstract, nor on the manual in isolation.

Insight 2: different documents in the same file carry different authentication requirements. Section 2.3.2 requires authentication for the certificate of free sale, while section 2.3.4 expressly states that the manufacturer representation document does not require consular legalisation. There is therefore no such thing as a uniform authentication approach for a Bolivian dossier; each document has to be judged on its own rule, and the plan should record which rule applies to which certificate rather than applying the strictest requirement to everything.

Insight 3: the manual already provides a route where no Bolivian consulate exists. Section 2.3.2 provides that where the country of origin has no Bolivian consular mission, the original is submitted together with certification by the Bolivian Ministry of Foreign Affairs. This supplies a fallback for the authentication chain and is relevant to manufacturers in jurisdictions where consular coverage is thin, because it converts an apparent dead end into a defined procedure.

Insight 4: confirmation should be documented and dated. An oral answer from a case officer is not a basis for a document strategy that will be executed over several months. A written query and a written reply, retained with the file, allow the manufacturer to demonstrate the basis on which the authentication route was chosen if the file is later examined under a different reading. The same discipline applies when the answer changes, since the date of the change is itself useful information for planning subsequent submissions.

4. Practical recommendations

1. Confirm in writing with AGEMED, before document preparation begins, whether the certificate of free sale will be accepted with an apostille or requires consular legalisation.
2. Complete the authentication of all documents in one pass once the answer is known, so that a change of route mid-project does not force rework across the whole set.
3. Treat the manufacturer representation document under section 2.3.4 as exempt from consular legalisation, preparing the original and completing the filing instead.
4. Keep the written confirmation on file with the submission, together with the date on which it was given, so the basis for the chosen route is documented.

5. Verification checklist

• □ The status and entry-into-force date of Bolivia’s accession to the Apostille Convention have been confirmed
• □ AGEMED has confirmed in writing the authentication position for the certificate of free sale
• □ The authentication requirement has been distinguished document by document
• □ The Ministry of Foreign Affairs route for cases without a consular mission has been confirmed
• □ The manufacturer representation document has been handled as requiring no consular legalisation

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers and authorised representatives with registration in Bolivia, including the authentication strategy for certificates of free sale and representation documents, written confirmation requests to AGEMED on current acceptance practice, and coordination of apostille and consular routes with the issuing authorities. For assistance with an authentication chain or a document plan for Bolivia, contact the GRZAN regulatory team at info@grzanglobal.com.

GRZAN applies a writing standard of conclusions first, traceable sources and verifiable figures to its regulatory publications, and follows the practice of AGEMED and the other authorities cited in this series as it develops. For a market access plan that resolves the authentication question before the document chain is built, the team welcomes your enquiry.